Regulus Therapeutics
Aug. 20, 2024
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity Regulus Announces Pricing of Public Offering of Common Stock Regulus Therapeutics Company Profile: Stock Performance & Earnings | PitchBook Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics - Sanofi (NASDAQ:SNY) - Benzinga | Regulus Therapeutics